HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 275, Issue 32, 24776-24780, August 11, 2000

This Article Abstract Full Text (PDF) All Versions of this Article: 275/32/24776    most recent M001938200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Polunovsky, V. A. Articles by Bitterman, P. B. Search for Related Content PubMed PubMed Citation Articles by Polunovsky, V. A. Articles by Bitterman, P. B. Social Bookmarking                      What's this?

Translational Control of the Antiapoptotic Function of Ras^*

Vitaly A. Polunovsky, Anne-Claude Gingras^§, Nahum Sonenberg^§, Mark Peterson, Annie Tan, Jeffrey B. Rubins, J. Carlos Manivel^¶, and Peter B. Bitterman

From the  Department of Medicine and the ^¶ Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota 55455 and the ^§ Department of Biochemistry, McGill University, Montreal, Quebec H3G IY6, Canada

Received for publication, March 7, 2000, and in revised form, April 28, 2000

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Activated Ras has been shown to provide powerful antiapoptotic signals to cells through well defined transcriptional and post- translational pathways, whereas translational control as a mechanism of Ras survival signaling remains unexplored. Here we show a direct relationship between assembly of the cap-dependent translation initiation apparatus and suppression of apoptosis by oncogenic Ras in vitro and in vivo. Decreasing protein synthesis with rapamycin, which is known to inhibit cap-dependent translation, increases the susceptibility of Ras-transformed fibroblasts to cytostatic drug-induced apoptosis. In contrast, suppressing global protein synthesis with equipotent concentrations of cycloheximide actually prevents apoptosis. Enforced expression of the cap-dependent translational repressor, the eukaryotic translation initiation factor (eIF) 4E-binding protein (4E-BPI), sensitizes fibroblasts to apoptosis in a manner strictly dependent on its ability to sequester eIF4E from a translationally active complex with eIF4GI and the co-expression of oncogenic Ras. Ectopic expression of 4E-BP1 also promotes apoptosis of Ras-transformed cells injected into immunodeficient mice and markedly diminishes their tumorigenicity. These results establish that eIF4E-dependent protein synthesis is essential for survival of fibroblasts bearing oncogenic Ras and support the concept that activation of cap-dependent translation by extracellular ligands or intrinsic survival signaling molecules suppresses apoptosis, whereas synthesis of proteins mediating apoptosis can occur independently of the cap.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Extracellular survival factors suppress the intrinsic apoptotic apparatus through cognate receptor kinases at the cell surface, which activate the proto-oncogene ras and a number of pleiotropic transcriptional and post-translational effector pathways (1). A major effector of Ras survival signaling is the serine/threonine protein kinase, Akt (2, 3). Transcriptional control is exerted by Akt-mediated phosphorylation of the Forkhead1 family transcription factor FKHRL1(4) and the transcription factor nuclear factor-B (5), which alter expression of apoptosis-related genes. Akt-mediated phosphorylation of the Bcl-2 family member Bad (6) and the cell death protease caspase-9 (7) is implicated in post-translational suppression of the intrinsic apoptotic machinery. Akt also regulates the FK506 binding-protein 12 (FKBP12)-rapamycin-associated protein/mammalian target of rapamycin (FRAP/mTOR),¹ a kinase which functions in the control of translation by activating two components of the protein synthesis apparatus: (i) the initiation complex binding the 5'-mRNA cap and (ii) the 40 S ribosomal protein S6 kinase, p70^s6k (8-11). However, data examining the importance of translational control in the mechanism of Ras survival signaling are lacking.

Translational control is usually exerted at the initiation step. In eukaryotes, the 5'-mRNA cap is bound by the eukaryotic translation initiation complex eIF4F, which consists of a bi- directional RNA helicase eIF4A, the docking protein eIF4G and the cap binding subunit eIF4E (12). A major target for regulation, eIF4E is considered to be rate limiting for translation initiation under most circumstances (13), and its up-regulation is associated with cell proliferation, suppression of apoptosis, and tumorigenicity (14, 15). The function of eIF4E is inhibited by members of the family of translational repressors, the eIF4E-binding proteins (4E-BPs, also known as PHAS) (13, 16). When hypophosphorylated, 4E-BPs compete with eIF4G for binding to eIF4E and sequester eIF4E in a nonfunctional complex. Upon hyperphosphorylation, 4E-BPs dissociate from the complex with eIF4E allowing it to form an active translation initiation complex (16, 17). To elucidate the role of translational control in Ras survival signaling, here we focus directly on the 5'-mRNA cap binding complex and examine the induction of apoptosis in cells transformed with oncogenic Ras after a generalized reduction in protein synthesis or after specific repression of cap-dependent translation initiation.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Generation of Clones and Transient Transfection-- Cloned rat embryo fibroblasts (CREF) and CREF/RasV12 (a gift from A. De Benedetti) were subcloned and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. The coding sequence of human 4E-BP1 was amplified by polymerase chain reaction and directionally cloned into the EcoRI and BamHI sites of the mammalian expression vector pSRpuro, (a kind gift from Dr. P. Jolicoeur, Institut de Recherches Cliniques, Montreal). To generate the eIF4E binding site deletion mutant (amino acids 54-63; 4E-BP1-), the 4E-BP1 coding sequence was cloned into the cytomegalovirus-based vector pACTAG-2, which was used as a template for polymerase chain reaction site-directed mutagenesis (18). Clones of CREF and CREF/RasV12 expressing wild type or mutant 4E-BP1 were generated using the FuGENE 6 (Roche Diagnostics) transfection technique. Selection of transfected cells was begun after 24 h with medium containing 1 µg/ml puromycin, and resistant clones were isolated after 12-16 days. CREF/RasV12s were also transiently transfected with a pACTAG-2 construct encoding hemagglutinin (HA)-tagged human 4E-BP1-wt, 4E-BP1-, or a vector carrying only the HA tag. To detect the level of HA expression by flow cytometry, cells were fixed with absolute ethanol and incubated for 16 h at 4 °C with mouse anti-HA IgG2_bk antibody (4 µg/ml, Roche Molecular Biochemicals) or with mouse isotype-specific IgG2_bk antibody (4 µg/ml, PharMingen) followed by incubation with fluorescein-conjugated anti-mouse IgG antibody (1:40, Sigma) for 30 min.

Immunoblot Analysis of Cap-bound Proteins-- Cell lysates (250 µl containing 250 µg of protein) were incubated with m⁷GTP-Sepharose resin (Amersham Pharmacia Biotech) to capture eIF4E and its binding partners (9). Samples were eluted with buffer containing 70 µM m⁷GTP. Cap-bound material was subjected to SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose. Blots were probed first for eIF4E (mouse monoclonal antibody, 1:500, Transduction Laboratories), then stripped and probed for 4E-BP1 (rabbit polyclonal antiserum 1:2500) (19), and stripped and probed a third time for eIF4GI (rabbit polyclonal antibody 1:4000) (20)

Apoptosis Assays-- Frequency of apoptosis was quantified by flow cytometric analysis of the percentage of cells with hypodiploid DNA content. Adherent and nonadherent cells were pooled, washed in phosphate-buffered saline, and fixed with ice-cold 70% ethanol for at least 1 h. Fixed cells were washed and incubated in propidium iodide stain mixture 50 µg/ml propidium iodide, 0.05% Triton X-100, 37 µg/ml EDTA, 100 units/ml ribonuclease in phosphate-buffered saline). After incubation for 45 min at 37 °C, DNA content was determined by quantitative flow cytometry using standard optics of the FACScan flow cytometer (Becton Dickinson) and the CellQuest program.

Tumorigenicity Assay-- Under sterile conditions, 3 × 10⁶ cells in phosphate-buffered saline were injected into each flank of immunodeficient mice (Nu Nu, Harlan). CREF/RasV12 cells were injected into one flank of each pair. In the opposite flank, we injected cells from each of the four independently derived CREF/Ras/BP1-wt clones or as a negative control, untransformed CREF. Tumor formation was documented photographically and quantified after 15 days by weight. Tumors were fixed in 10% buffered formalin overnight, processed for routine histology, and examined by a pathologist (JCM) in a blinded fashion.

Statistics-- Results of flow cytometry were tabulated as the mean ± S.D. of two to five separate experiments. In each experiment, all conditions were examined in duplicate or triplicate. For analysis of tumorigenicity, mitotic and apoptotic indices represent the average number of events/×600 microscopic field (quantified in 10 fields); and tumor weights (CREF/RasV12 versus CREF/Ras/BP1 clones) were compared using a paired t test on a log scale.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Activation of Apoptosis in Ras-transformed Fibroblasts by Rapamycin-- We used a cell system (21) in which constitutively expressed oncogenic RasV12 enables CREF to survive in otherwise lethal concentrations of cytostatic drugs (nongenotoxic, lovastatin; genotoxic, camptothecin, Fig. 1). The FRAP/mTOR inhibitor rapamycin completely abrogated Ras-dependent resistance to drug-induced cell death (Fig. 1b) and even when applied as a single agent, stimulated apoptosis in cells expressing activated Ras. This proapoptotic effect of rapamycin was not observed in nontransformed fibroblasts. These observations confirm a dual proapoptotic and antiapoptotic function for RasV12 (2) and implicate FRAP/mTOR in Ras-dependent rescue from both Ras-activated and drug-triggered apoptotic pathways.

View larger version (32K): [in this window] [in a new window]   Fig. 1.   Rapamycin suppresses Ras-induced chemoresistance. a, expression of Ras protein in CREF/Neo and CREF/RasV12. b, apoptosis was assessed after incubation (24 h, 37 °C) with or without 75 nM rapamycin in medium alone (solid bar) or medium supplemented either with 5 µM lovastatin (striped bar) or 75 nM camptothecin (open bar). Values shown represent the mean ± S.D. (n = 3) of the percentage of cells with subdiploid DNA content. c and d, lovastatin-induced apoptosis in association with suppression of protein synthesis by rapamycin or cycloheximide. The rates of protein synthesis and lovastatin-induced apoptosis were quantified in parallel cultures exposed for 24 h to different concentrations of either rapamycin (c) or cycloheximide (d). Protein synthesis is displayed as a percent of that observed without inhibitors.

When rapamycin was added to Ras-transformed cells, it caused a dose-dependent decline in protein synthesis, which paralleled its ability to sensitize cells to lovastatin-induced apoptosis (Fig. 1c). Of note, equipotent doses of the peptide elongation inhibitor cycloheximide actually blocked apoptosis (Fig. 1d), demonstrating that the execution of lovastatin-induced cell death requires global protein synthesis. These results suggest that a generalized inhibition of mRNA translation is not the means by which rapamycin exerts its proapoptotic effect, rather they point toward a selective inhibition of antiapoptotic mRNA translation or a mechanism independent of its ability to repress translation.

Activation of Apoptosis by 4E-BP1 in Fibroblasts Expressing Oncogenic Ras-- FRAP/mTOR has a dual function in the regulation of translation. It stimulates protein synthesis by regulating ribosomal biogenesis through p70s6k (22) and specifically activates cap-dependent translation by phosphorylating the 4E-BPs (8-10). Our previous work linking suppression of apoptosis to the cap-dependent translation initiation apparatus (15) led us to explore whether the 4E-BPs modulate Ras-dependent viability and chemoresistance. CREF/RasV12 and CREF cells were transfected with BP1-wt linked to a puromycin selectable marker or with vector carrying only the selectable marker, and puromycin-resistant clones were isolated. Four CREF/Ras/BP1-wt and four CREF/BP1-wt clonal lines were developed and assayed for steady state levels of 4E-BP1.

Under conditions in which expression of endogenous 4E-BP1 in all mock-transfected cells was undetectable, BP1-wt-transfected clones displayed a range of ectopic 4E-BP1 expression. Western blot analysis performed on total cellular extracts revealed human 4E-BP1 represented by hypo-(), intermediate (), and hyperphosphorylated () forms (9, 16) (Fig. 2a), with the  form appearing as a doublet in some of the clones. Quantification of apoptosis by flow cytometry revealed that ectopic 4E-BP1 significantly increased the rate of spontaneous apoptosis in Ras-transformed cells in a dose-dependent manner. This 2-8-fold augmentation in basal apoptotic frequency was approximately doubled in the presence of lovastatin (Fig. 2a). In sharp contrast to the results with transformed CREF/RasV12, 4E-BP1 did not activate apoptosis in nontransformed parental CREF lacking activated Ras (Fig. 2b). Whereas many cells comprising the CREF/Ras/BP1-wt clonal lines displayed morphological hallmarks of apoptosis (Fig. 2c), ectopic expression of 4E-BP1 did not alter the morphology of CREF (Fig. 2d). Thus, ectopic 4E-BP1 shifted Ras signaling from suppression to induction of apoptosis.

View larger version (31K): [in this window] [in a new window]   Fig. 2.   4E-BP1 sensitizes Ras-transformed cells to apoptosis. Apoptosis was quantified by flow cytometry (a and b) and visualized by acridine orange staining (c and d). Apoptosis and immunoblot analysis of 4E-BP1 expression in clonal cell lines of CREF/Ras/V12 (a) and CREF (b) transfected with a construct encoding wild type 4E-BP1 are shown. Cells were cultured for 24 h in the presence (closed circles) or absence (open circles) of 5 µM lovastatin. Each point represents the mean ± S.D. (n = 3) (c and d). Micrographs of Ras-transformed (c) and nontransformed CREF (d) expressing wild type 4E-BP1 (×300) or puromycin vector (shown in the inset, ×75).

Relationship between Apoptosis and Sequestration of eIF4E by 4E-BP1-- To investigate whether the proapoptotic function of 4E-BP1 in CREF/RasV12 was directly related to its ability to sequester eIF4E from the translationally active eIF4E-eIF4GI complex, cellular extracts from each clonal line of CREF/Ras/BP1-wt were incubated with the cap analogue m⁷GTP-agarose to capture eIF4E and its cellular binding partners. The levels of cap-bound eIF4E, 4E-BP1, and eIF4GI were quantified by immunoblotting and densitometry. Each CREF/RasV12/BP1-wt clone displayed eIF4E associated with significantly increased amounts of fast migrating, hypophosphorylated 4E-BP1 (Fig. 3a). Consistent with this, clones ectopically expressing 4E-BP1-wt generally manifested decreased amounts of eIF4GI bound to eIF4E. Although clone 2 revealed relatively high levels of eIF4GI, there was also an increased amount of eIF4E in the m⁷GTP-captured material. Thus, the ratio of eIF4GI to cap analogue-bound eIF4E was significantly decreased in all 4E-BP1 clones tested, confirming the ability of overexpressed 4E-BP1 to inhibit assembly of the eIF4F translation pre-initiation complex. The apoptotic frequency in clones co-expressing activated Ras and 4E-BP1 was proportional to the amount of 4E-BP1 complexed with eIF4E (Fig. 3b) and was inversely related to the eIF4GI/eIF4E ratio (Fig. 3c), a relationship observed in the presence and absence of lovastatin. Thus, stimulation of apoptotic death by 4E-BP1 was a function of its activity in competitively displacing eIF4GI from eIF4E.

View larger version (29K): [in this window] [in a new window]   Fig. 3.   4E-BP1-promoted apoptosis in Ras-transformed cells is associated with displacement of translation factor eIF4GI from eIF4E. a, immunoblot analysis of 4E-BP1 and eIF4GI associated with cap-bound eIF4E in clones of CREF/RasV12 ectopically expressing wild type 4E-BP1. b and c, apoptosis is shown as a function of the 4E-BP1/eIF4E (b) or eIF4G/eIF4E (c) ratio in the indicated CREF/Ras/BP1-wt clones incubated in growth medium for 24 h in the presence (closed circles) or absence (open circles) of 5 µM lovastatin. d, 4E-BP1 lacking an eIF4E binding domain does not promote apoptosis. Shown are nonspecific green fluorescence (open histograms), expression of HA (closed histograms), and DNA content (shaded histograms) in CREF/RasV12 transfected with an empty HA vector, an HA-tagged wild type 4E-BP1, or an HA-tagged eIF4E binding site deletion mutant, 4E-BP1-. The results of a representative experiment are shown (three independent transfection experiments yielded similar results).

To determine whether the interaction of 4E-BP1 with elF4E was a strict requirement for the proapoptotic function of 4E-BP1 in Ras-transformed cells, we utilized a 4E-BP1 deletion mutant (4E-BP1-), which lacks the eIF4E binding site (18). Transient transfection of CREF/RasV12 with 4E-BP1-wt enhanced spontaneous apoptosis and sensitized cells to lovastatin in a manner similar to that observed in the stable CREF/RasV12/BP1-wt clones, suggesting that activation of apoptosis in 4E-BP1-transfected clones was not due to secondary genetic changes during clonal selection (Fig. 3d). In marked contrast, transient transfection with 4E-BP1- had minimal effects on viability, despite similar levels of 4E-BP1 expression. Thus, the ability of 4E-BP1 to bind eIF4E was essential for its blockade of Ras-induced survival signaling.

Effect of 4E-BP1 on Apoptosis of Ras-transformed Fibroblasts in Vivo-- Prior studies have shown that ectopic 4E-BP1 decreases the mitotic index and tumorigenicity of NIH 3T3 cells transformed with either eIF4E or src (23); apoptosis was not evaluated. To study all three parameters in Ras-transformed fibroblasts, we injected cells from the CREF/Ras/BP1 clonal lines into immunodeficient mice. Tumors formed by each CREF/Ras/BP1 line tested were less than one-third the size of those formed by mock-transfected CREF/Ras V12, with less visible vascularity (Fig. 4, a and b). All CREF/RasV12 tumors contained cells forming ill-defined fascicles with ovoid nuclei and an elongated cytoplasm; apoptotic cells were rarely observed (Fig. 4c). In contrast, tumors formed by cells ectopically expressing 4E-BP1 displayed more nuclear pleomorphism and most microscopic fields contained scattered apoptotic cells (Fig. 4, d and e). Ectopic 4E-BP1 decreased the mitotic index of the tumor cells by approximately one-third and dramatically increased their apoptotic frequency by nearly 5-fold (Fig. 4f). Untransformed CREF did not form tumors. These findings establish that suppression of apoptosis in Ras-transformed cells in vivo depends in part on cap-dependent translation, a function that was not rescued by transcriptional or post-translational processes.

View larger version (76K): [in this window] [in a new window]   Fig. 4.   Increased expression of wild type 4E-BP1 suppresses tumorigenicity of activated Ras. CREF/RasV12 cells and cells from each of the CREF/RasV12 clonal lines expressing different levels of wild type 4E-BP1 (or in one pair, untransformed CREF) were introduced into nude mice and allowed to grow for 15 days. Shown are: a, a representative photograph (CREF/RasV12, right flank; CREF/Ras/BP1 clone 17, left flank); b, tumor weight (mean ± S.E.); difference between CREF/RasV12 and CREF/Ras/BP1 in panel b significant at p < 0.0001. c, d, and e, illustrative histological sections (×600). CREF/RasV12 tumors consisted of uniform spindle shaped cells with numerous bipolar mitoses (c). CREF/Ras/BP1 tumors were comprised of more pleomorphic cells with a lower mitotic frequency, tripolar mitoses, and scattered apoptotic bodies (d and e, arrows designate apoptotic cells). F, mitotic (solid bars) and apoptotic (striped bars) frequency (mean ± S.E.)/×600 microscopic field in tumors formed by CREF/RasV12 or CREF/Ras/BP1 clonal lines.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

For nearly four decades, global translational control has been recognized as a fundamental regulatory process in biology (24). More recently, examples of selective control have emerged involving regulation at the translation initiation step, particularly in the integration of pleiotropic responses leading to differentiation, proliferation, and survival (25, 26). Here we focus on the translational apparatus itself, examining initiation events involving the mRNA cap-binding protein eIF4E and its most abundant repressor, 4E-BP1. We find that concentrations of rapamycin that are known to inhibit 4E-BP1 phosphorylation and cap-dependent protein synthesis (10) sensitize fibroblasts carrying activated Ras to apoptosis, whereas nonselective inhibition of global protein synthesis by the peptide elongation inhibitor cycloheximide actually blocks apoptosis. We further show that enforced expression of 4E-BP1 in Ras-transformed fibroblasts activates apoptosis, eliminates resistance to cytostatic drugs, and inhibits tumorigenicity. In contrast, cell viability is unaltered when 4E-BP1 is ectopically expressed in nontransformed cells. The proapoptotic activity of 4E-BP1 is strictly dependent on its ability to sequester the mRNA cap-binding protein, eIF4E, thus preventing assembly of an active pre-initiation translation complex. These results add cap-dependent translation to the established transcriptional and post-translational mechanisms involved in the regulation of apoptosis by oncogenic Ras and identify a translationally regulated step as essential for Ras-dependent drug resistance.

Mounting evidence now suggests that the translational machinery subserves an important role in the regulation of apoptosis (15, 27, 28). In our study design, we experimentally separate the viability effects of global versus cap-dependent translation. We find here that up to an 80% reduction of global protein synthesis with cycloheximide actually blocks apoptosis, whereas similar levels of translational repression with the FRAP/mTOR inhibitor rapamycin or ectopic expression of the cap-specific repressor 4E-BP1 have a profound proapoptotic effect. The importance of cap-dependent protein synthesis in viability regulation is further supported by work demonstrating that the translation initiation factor eIF4G is cleaved early in the process of apoptosis (29-31) leading to a shut off of cap-dependent protein synthesis. In addition, recent reports implicate cap-independent translation through internal ribosomal entry sites in the synthesis of some proapoptotic proteins (27, 32), and for Myc where detailed studies have been carried out, translation is sustained even during apoptosis by initiation utilizing an internal ribosomal entry site (32).

The downstream effector proteins linking the cap-dependent translation initiation apparatus to the apoptotic machinery and the precise mechanisms regulating the translation of their cognate mRNAs are unknown. Prior studies have identified several candidate mRNAs encoding proteins subject to strong cap-dependent translational control that positively and negatively regulate cell viability including p53, Mdm-2, Fas/Apo-1, members of the Bcl-2 family, and cyclin D1 (33-35). Among these, we have recently shown that translational activation of cyclin D1 by eIF4E functions in the suppression of Myc-induced apoptosis (35). In our view, the limited data available fit best with the concept that activation of cap-dependent protein synthesis by extracellular ligands or intrinsic signaling molecules results in a profile of cellular proteins that suppresses apoptosis, whereas translation of mRNA encoding proapoptotic proteins can be initiated even during apoptosis in a cap-independent manner.

The present findings add to our current understanding of cell biology by highlighting new regulatory events integral to cancer cell survival. Available data suggest that eIF4E is a powerful oncogene (14, 36), whereas its antagonist 4E-BP1 functions as a tumor suppressor gene (23, 37). Nonmalignant cells can apparently function over a wide range of 4E-BP1 expression. Its absence in knockout mice results in no apparent phenotypic changes (38), and here we find that even dramatic overexpression in nontransformed fibroblasts is compatible with physiological function. Against the background of oncogenic Ras, however, 4E-BP1 exerts powerful control over cell growth, viability, and susceptibility to cytostatic drugs. These findings suggest that translational repressors may constitute a significant component of the mammalian tumor surveillance system. In addition, our work identifies a novel mechanism whereby tumor cells bearing oncogenic Ras can acquire resistance to genotoxic and nongenotoxic therapeutic agents. Our data thus provide direct evidence linking the fundamental biological process of cap-dependent translation initiation with suppression of apoptosis by activated Ras.

	ACKNOWLEDGEMENTS

We thank A. De Benedetti for cell lines and discussion, P. Jolicoeur for the pSR vector, J. Geagea for help cloning pSR-BPI, J. Murray and Darlene Charboneau for technical assistance, the University of Minnesota Cancer Center Biostatistical Core for assistance in study design and data analysis, and B. Raught for critical review of the manuscript.

	FOOTNOTES

^* This work was supported by NHLBI, National Institutes of Health-funded SCOR Grant 2P50-HL50152, a grant from the National Cancer Institute of Canada, a doctoral award from the Medical Research Council of Canada, and the M.D. Ph.D. program of the University of Minnesota Medical School.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 612-624-0999; Fax: 612-625-2174; E-mail: bitte001@tc.umn.edu..

Published, JBC Papers in Press, May 12, 2000, DOI 10.1074/jbc.M001938200

	ABBREVIATIONS

The abbreviations used are: FRAP/mTOR, FKBP12-rapamycin-associated protein/mammalian target of rapamycin; eIF, lukaryotic translation initiation factor; 4E-BP, eIF4E-binding protein; CREF, cloned rat embryo fibroblasts; HA, hemagglutinin; BP1-wt, wild type 4E-BP1.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				K. J. Mavrakis, H. Zhu, R. L.A. Silva, J. R. Mills, J. Teruya-Feldstein, S. W. Lowe, W. Tam, J. Pelletier, and H.-G. Wendel Tumorigenic activity and therapeutic inhibition of Rheb GTPase Genes & Dev., August 15, 2008; 22(16): 2178 - 2188. [Abstract] [Full Text] [PDF]

				B. Culjkovic, K. Tan, S. Orolicki, A. Amri, S. Meloche, and K. L.B. Borden The eIF4E RNA regulon promotes the Akt signaling pathway J. Cell Biol., April 3, 2008; 181(1): 51 - 63. [Abstract] [Full Text] [PDF]

				H.-G. Wendel, R. L.A. Silva, A. Malina, J. R. Mills, H. Zhu, T. Ueda, R. Watanabe-Fukunaga, R. Fukunaga, J. Teruya-Feldstein, J. Pelletier, et al. Dissecting eIF4E action in tumorigenesis Genes & Dev., December 15, 2007; 21(24): 3232 - 3237. [Abstract] [Full Text] [PDF]

				X. Wan and L. J. Helman The Biology Behind mTOR Inhibition in Sarcoma Oncologist, August 1, 2007; 12(8): 1007 - 1018. [Abstract] [Full Text] [PDF]

				J. Hu, J. Straub, D. Xiao, S. V. Singh, H.-S. Yang, N. Sonenberg, and J. Vatsyayan Phenethyl Isothiocyanate, a Cancer Chemopreventive Constituent of Cruciferous Vegetables, Inhibits Cap-Dependent Translation by Regulating the Level and Phosphorylation of 4E-BP1 Cancer Res., April 15, 2007; 67(8): 3569 - 3573. [Abstract] [Full Text] [PDF]

				K. W. Adams and G. M. Cooper Rapid Turnover of Mcl-1 Couples Translation to Cell Survival and Apoptosis J. Biol. Chem., March 2, 2007; 282(9): 6192 - 6200. [Abstract] [Full Text] [PDF]

				A. Panner, J. L. Nakamura, A. T. Parsa, P. Rodriguez-Viciana, M. S. Berger, D. Stokoe, and R. O. Pieper mTOR-Independent Translational Control of the Extrinsic Cell Death Pathway by RalA Mol. Cell. Biol., October 15, 2006; 26(20): 7345 - 7357. [Abstract] [Full Text] [PDF]

				J. Cui, S.-Y. Han, C. Wang, W. Su, L. Harshyne, M. Holgado-Madruga, and A. J. Wong c-Jun NH2-Terminal Kinase 2{alpha}2 Promotes the Tumorigenicity of Human Glioblastoma Cells. Cancer Res., October 15, 2006; 66(20): 10024 - 10031. [Abstract] [Full Text] [PDF]

				S. K. Mungamuri, X. Yang, A. D. Thor, and K. Somasundaram Survival Signaling by Notch1: Mammalian Target of Rapamycin (mTOR)-Dependent Inhibition of p53. Cancer Res., May 1, 2006; 66(9): 4715 - 4724. [Abstract] [Full Text] [PDF]

				B. A. Jacobson, M. D. Alter, M. G. Kratzke, S. P. Frizelle, Y. Zhang, M. S. Peterson, S. Avdulov, R. P. Mohorn, B. A. Whitson, P. B. Bitterman, et al. Repression of Cap-Dependent Translation Attenuates the Transformed Phenotype in Non-Small Cell Lung Cancer Both In vitro and In vivo. Cancer Res., April 15, 2006; 66(8): 4256 - 4262. [Abstract] [Full Text] [PDF]

				R. E. Brown, P. L. Zhang, M. Lun, S. Zhu, P. K. Pellitteri, A. Law, G. C. Wood, and T. L. Kennedy Morphoproteomic and Pharmacoproteomic Rationale for mTOR Effectors as Therapeutic Targets in Head and Neck Squamous Cell Carcinoma Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 273 - 282. [Abstract] [Full Text] [PDF]

				L. Hui, V. Rodrik, R. M. Pielak, S. Knirr, Y. Zheng, and D. A. Foster mTOR-dependent Suppression of Protein Phosphatase 2A Is Critical for Phospholipase D Survival Signals in Human Breast Cancer Cells J. Biol. Chem., October 28, 2005; 280(43): 35829 - 35835. [Abstract] [Full Text] [PDF]

				R. E. Brown Morphoproteomic Analysis of Osteolytic Langerhans Cell Histiocytosis with Therapeutic Implications Ann. Clin. Lab. Sci., April 1, 2005; 35(2): 131 - 136. [Abstract] [Full Text] [PDF]

				H. ZAKOWICZ, H.-S. YANG, C. STARK, A. WLODAWER, N. LARONDE-LEBLANC, and N. H. COLBURN Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI RNA, March 1, 2005; 11(3): 261 - 274. [Abstract] [Full Text] [PDF]

				G. HERNANDEZ, P. VAZQUEZ-PIANZOLA, J. M. SIERRA, and R. RIVERA-POMAR Internal ribosome entry site drives cap-independent translation of reaper and heat shock protein 70 mRNAs in Drosophila embryos RNA, November 18, 2004; 10(11): 1783 - 1797. [Abstract] [Full Text] [PDF]

				Y. Yue, J. Lypowy, N. Hedhli, and M. Abdellatif Ras GTPase-activating Protein Binds to Akt and Is Required for Its Activation J. Biol. Chem., March 26, 2004; 279(13): 12883 - 12889. [Abstract] [Full Text] [PDF]

				D. J. Perkins and G. N. Barber Defects in Translational Regulation Mediated by the {alpha} Subunit of Eukaryotic Initiation Factor 2 Inhibit Antiviral Activity and Facilitate the Malignant Transformation of Human Fibroblasts Mol. Cell. Biol., March 1, 2004; 24(5): 2025 - 2040. [Abstract] [Full Text] [PDF]

				N. Kaminski, J. A. Belperio, P. B. Bitterman, L. Chen, S. W. Chensue, A. M.K. Choi, S. Dacic, J. H. Dauber, R. M. du Bois, J. J. Enghild, et al. Idiopathic Pulmonary Fibrosis Am. J. Respir. Cell Mol. Biol., September 1, 2003; 29(3): S1 - 105. [Full Text] [PDF]

				S. Li, T. Takasu, D. M. Perlman, M. S. Peterson, D. Burrichter, S. Avdulov, P. B. Bitterman, and V. A. Polunovsky Translation Factor eIF4E Rescues Cells from Myc-dependent Apoptosis by Inhibiting Cytochrome c Release J. Biol. Chem., January 24, 2003; 278(5): 3015 - 3022. [Abstract] [Full Text] [PDF]

				F. Meric and K. K. Hunt Translation Initiation in Cancer: A Novel Target for Therapy Mol. Cancer Ther., September 1, 2002; 1(11): 971 - 979. [Abstract] [Full Text] [PDF]

				J. S. Shenberger, M. H. Adams, and S. G. Zimmer Oxidant-Induced Hypertrophy of A549 Cells Is Accompanied by Alterations in Eukaryotic Translation Initiation Factor 4E and 4E-Binding Protein-1 Am. J. Respir. Cell Mol. Biol., August 1, 2002; 27(2): 250 - 256. [Abstract] [Full Text] [PDF]

				S. Li, N. Sonenberg, A.-C. Gingras, M. Peterson, S. Avdulov, V. A. Polunovsky, and P. B. Bitterman Translational Control of Cell Fate: Availability of Phosphorylation Sites on Translational Repressor 4E-BP1 Governs Its Proapoptotic Potency Mol. Cell. Biol., April 15, 2002; 22(8): 2853 - 2861. [Abstract] [Full Text] [PDF]

				J. C. Wolfman, T. Palmby, C. J. Der, and A. Wolfman Cellular N-Ras Promotes Cell Survival by Downregulation of Jun N-Terminal Protein Kinase and p38 Mol. Cell. Biol., March 1, 2002; 22(5): 1589 - 1606. [Abstract] [Full Text] [PDF]

				A.-C. Gingras, B. Raught, and N. Sonenberg Regulation of translation initiation by FRAP/mTOR Genes & Dev., April 1, 2001; 15(7): 807 - 826. [Full Text]

< This Article Abstract Full Text (PDF) All Versions of this Article: 275/32/24776    most recent M001938200v1 Alert me when this article is cited